ArticleRadiation oncology (London, England)2026
Current clinical practice of radiotherapy for the non-operative treatment of patients with unresectable locally recurrent rectal cancer: results of a national survey of the dutch society for radiotherapy and oncology.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background and purposeOver half of patients with locally recurrent rectal cancer (LRRC) are ineligible for curative-intent multimodality treatment, typically including neoadjuvant treatment followed by surgery, due to unresectable disease, distant metastases, and/or frailty. Non-operative management for unresectable LRRC may include (chemo)(re-)irradiation, but evidence remains scarce. This study explores the current clinical practice of radiotherapy for LRRC in the Netherlands within this setting. MATERIALS AND
methodsA web-based survey was designed and distributed to members of the Dutch Society of Radiation Oncology between December 2024 and February 2025. The survey comprised 28 items, addressing clinical indications, target delineation, treatment planning, dose and fractionation, radiotherapy techniques and knowledge gaps in current clinical practice.
results23 radiation oncologists from 18 out of 21 Dutch institutes completed the survey. While agreement existed regarding indications for radiotherapy in the non-operative management for LRRC, marked variability was observed in dose and fractionation schedules and target volume delineation. There seemed to be no consensus on response evaluation or follow-up schedules. Reported clinical challenges included patient heterogeneity, absence of evidence-based guidelines, limited knowledge on radiation-induced toxicity, difficulties estimating prognosis and management of therapy-resistant symptoms.
conclusionsThis national survey highlights the clinical heterogeneity and lack of consensus regarding radiotherapy for unresectable LRRC. Variations in dose and fractionation schedules, target volume delineation and follow-up underscore the need for prospective studies. Future research initiatives should prioritize optimal dose and fractionation schedules and the role of dose escalation, while integrating quality assurance programs and patient-reported outcomes to guide development of evidence-based recommendations for this complex patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.